Lineage Cell Therapeutics, Inc.
AMEX:LCTX · New York Stock Exchange American
-$0.04 today
Vol 0.85M · Avg 1.19M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-142.6%
avg -47.5%
ROIC
-19.7%
avg -32.5%
ROA
-56.4%
avg -22.9%
Analysis
ROIC is currently the strongest return metric at -19.7% versus its period average of -32.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Brian Culley | Chief Executive Officer, President & Director | $1.23M | — | 55 | $255,516.00 | 0.10% |
Jill Ann Howe | Chief Financial Officer | $718,000.00 | — | 50 | $1.05M | 0.42% |
George A. Samuel | General Counsel & Company Secretary | $690,300.00 | — | 45 | $900,000.00 | 0.36% |
Brandi L. Roberts | Consultant | $407,450.00 | — | 52 | $616,700.00 | 0.25% |
Harold D. Waitz | Vice President of Regulatory Affairs & Quality Control | $90,000.00 | — | 84 | $186,246.00 | 0.07% |
Alexandra Hernandez | Senior Director of Finance & Controller | — | — | — | $0.00 | <0.01% |
Charlotte Hubbert | Vice President of Corporate Strategy & Development | — | — | — | — | — |
Priyantha Herath | Senior VP & Head of Clinical Operations | — | — | — | — | — |
Rami Skaliter | Chief Executive Officer of Cell Cure Neurosciences | — | — | 68 | — | — |
Ioana C. Hone | Director of Investor Relations | — | — | — | $75,000.00 | 0.03% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$24,375.00
Sells
0
$0.00
Net Sentiment
+$24,375.00
Net buying
Most Active
Culley Brian M
1 transactions
Analysis
Insiders reported 1 buys worth $24,375.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $24,375.00. Culley Brian M was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +14.4% | +41.7% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +14.4% over three years. Forward estimates point to Revenue at +41.7% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Omeros Corporation
NASDAQ:OMER
$748.36M
Neurogene Inc.
NASDAQ:NGNE
$500.92M
Ocugen, Inc.
NASDAQ:OCGN
$426.54M
PureTech Health plc
NASDAQ:PRTC
$421.39M
Autolus Therapeutics plc
NASDAQ:AUTL
$412.12M
Benitec Biopharma Inc.
NASDAQ:BNTC
$318.11M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$195.88M
Galectin Therapeutics Inc.
NASDAQ:GALT
$184.16M
ADC Therapeutics S.A.
NYSE:ADCT
$138.00M
Who manages LCTX?
Lineage Cell Therapeutics, Inc. (LCTX) lists 10 active executives. The top listed executive is Brandi L. Roberts, Consultant.
Are LCTX insiders buying or selling?
Recent insider activity shows net buying of $44.17M.
Explore More
Continue the stock analysis
Jump to another research area for this company.